15,622 Johnson & Johnson $JNJ Shares Sold by Blume Capital Management Inc.

Key Points

• Blume Capital Management cut its Johnson & Johnson stake by 34.7% in the third quarter, selling 15,622 shares and retaining 29,461 shares valued at approximately $7.8 million. Institutional investors collectively own 69.55% of JNJ.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $275.92 average price target, although Johnson Rice downgraded the stock to “Hold.”
• Johnson & Johnson exceeded quarterly earnings expectations, reporting $2.59 in adjusted EPS and $25.40 billion in revenue, while maintaining a quarterly dividend of $1.34 per share, equivalent to a 2.0% yield.

Blume Capital Management Inc. lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 34.7% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 29,461 shares of the company's stock after selling 15,622 shares during the period. Blume Capital Management Inc.'s holdings in Johnson & Johnson were worth $7,799,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Silver Coast Investments LLC boosted its stake in shares of Johnson & Johnson by 3.8% in the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock worth $271,000 after acquiring an additional 39 shares during the period. Townsend Asset Management Corp NC ADV grew its position in shares of Johnson & Johnson by 0.6% during the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock worth $1,630,000 after purchasing an additional 39 shares in the last quarter. Triumph Capital Management raised its stake in Johnson & Johnson by 1.6% during the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company's stock valued at $643,000 after purchasing an additional 39 shares during the period. Kwmg LLC raised its stake in Johnson & Johnson by 1.7% during the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company's stock valued at $631,000 after purchasing an additional 39 shares during the period. Finally, Cypress Wealth Services LLC lifted its holdings in Johnson & Johnson by 0.4% in the 3rd quarter. Cypress Wealth Services LLC now owns 10,618 shares of the company's stock worth $2,705,000 after purchasing an additional 39 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Johnson Rice downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Wednesday, October 21st. Scotiabank reissued an "outperform" rating and issued a $305.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. UBS Group set a $270.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 14th. Freedom Capital raised shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 16th. Finally, Argus set a $300.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $275.92.

Insider Activity

In other news, EVP Elizabeth Forminard sold 15,918 shares of the company's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. This represents a 48.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 64,515 shares of company stock worth $17,271,766. 0.16% of the stock is currently owned by corporate insiders.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ is included among pharmaceutical companies with potential arthritis-treatment growth, supported by drug sales, clinical progress and regulatory expansion. This reinforces the outlook for its Innovative Medicine business and future cash generation. The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
• Positive Sentiment: The company will hold an Enterprise Business Review on December 8, when management is expected to provide additional detail on its Innovative Medicine and MedTech pipelines, long-term strategy and growth opportunities. The event could offer catalysts if the company raises confidence in future earnings. Johnson & Johnson to Host Enterprise Business Review
• Neutral Sentiment: JNJ has gained roughly 97% over three years, prompting investors to assess whether its valuation is supported by expected cash flow. Oncology trial developments and MedTech performance could materially influence that assessment. Johnson & Johnson Stock Trades At A Discount Following Its 97% Run
• Negative Sentiment: Ongoing attention to a talc-related charge adds legal and cash-flow uncertainty, while investors continue to monitor the broader talc litigation overhang. What Does the Talc Charge Mean for Johnson & Johnson Going Forward?
• Negative Sentiment: Reports of approximately $34.7 million in net ETF selling represent a modest technical headwind, although such flows do not necessarily reflect a change in JNJ’s fundamentals. Johnson & Johnson Sees $34.7 Million in Net ETF Selling
• Negative Sentiment: Pomerantz LLP is investigating potential claims on behalf of JNJ investors. The announcement does not establish wrongdoing, but it adds to headline and litigation risk. Investor Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Johnson & Johnson

Johnson & Johnson Stock Up 0.9%

NYSE JNJ opened at $271.17 on Thursday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The company has a market capitalization of $652.78 billion, a P/E ratio of 41.09, a P/E/G ratio of 2.61 and a beta of 0.21. Johnson & Johnson has a one year low of $184.66 and a one year high of $281.07. The stock has a 50 day moving average price of $265.60 and a 200-day moving average price of $246.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analysts' expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. Johnson & Johnson's quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson's payout ratio is 81.21%.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.